What is Invivoscribe?
Invivoscribe is a developer of precision molecular diagnostic assays, reagents, software, and clinical laboratory services. The company's offerings are designed to assist physicians in the detection and monitoring of blood cancers, thereby guiding treatment decisions and supporting the advancement of personalized oncology care through companion diagnostics and biomarker testing.
How much funding has Invivoscribe raised?
Invivoscribe has raised a total of $5M across 1 funding round:
Debt
$5M
Debt (2020): $5M with participation from PPP
Key Investors in Invivoscribe
PPP
Public-Private Partnership
What's next for Invivoscribe?
The recent major strategic investment suggests Invivoscribe is poised for a scaling phase, likely focusing on expanding its diagnostic capabilities, enhancing its software platforms, and broadening its reach in the personalized oncology market. This capital infusion is expected to fuel further innovation in biomarker testing and companion diagnostics, reinforcing its role in precision medicine.
See full Invivoscribe company page